Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Siglec-3 (CD33) and Siglec-8 ligands

ABSTRACT: Identification of human brain ligand for the microglial inhibitory receptors Siglec-3 (CD33) and Siglec-8

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Ronald L Schnaar

PROVIDER: PXD032064 | JPOST Repository | Mon Mar 07 00:00:00 GMT 2022

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	KA_Ron-%206%20proteins%2020ppm.mzML	Mzml
	KA_Ron-%20all%20human%2020ppm.msf	Msf
	KA_Ron-reviewed%20all%20human%2020ppm.xlsx	Xlsx
	KA_Ron.raw	Raw

Items per page:

1 - 4 of 4

Similar Datasets

E-GEOD-50161

Project description:Expression data from human brain tumors and human normal brain

2025-01-24 | E-GEOD-50161 | ExpressionAtlas

Cell array 10000 hybridization

Project description:The incubation of a 10,000 member PNA-encoded peptide library with cells over-expressing the alpha(v)beta(3) and alpha(v)beta(5) integrins (D54) or CCR6 (HEK293T-CCR6) followed by microarray analysis allowed detailed information on the interaction between peptide-ligands and cell surface receptors to be extracted. This allowed the identification of new cell specific ligands for alpha(v)beta(3) and alpha(v)beta(5) integrins and CCR6 and offers an approach to ligand discovery that allows the comparative, competitive and simultaneous analysis of different cell types for the identification of differences in surface-receptor ligands and/or receptor expression between cell types.

2011-08-10 | E-MEXP-3103 | biostudies-arrayexpress

Identification of RIFIN binding to KIR receptor from RIFIN expression library of Plasmodium flaicparum.

Project description:To discriminate between our own cells and those of a pathogen, natural killer cells are armed with inhibitory and activating immune receptors. The balance in signalling mediated by these receptors determines whether an NK cell is activated to destroy a target cell. In some cases, such as the KIRs, immune receptors are found in pairs, with inhibitory and activating receptors containing nearly identical extracellular ligand-binding domains, coupled to different intracellular signalling domains1. Previous studies have shown that RIFINs, displayed on surfaces of Plasmodium falciparum-infected erythrocytes, can bind to inhibitory immune receptors and dampen NK cell activation2,3, reducing parasite killing. However, no pathogen-derived ligand has been identified for any activating receptor. Here, we identify a clade of RIFINs that bind to inhibitory immune receptor KIR2DL1 more strongly than KIR2DL1 binds the human ligand, MHC class I. We demonstrate that this interaction mediates inhibitory signaling and suppresses the activation of KIR2DL1-expressing NK cells. We show that KIR2DL1-binding RIFINs are abundant in field-isolated strains from both Africa and Asia and reveal how two RIFINs bind KIR2DL1. We also demonstrate that the RIFIN binding surface of KIR2DL1 is conserved in the cognate activating immune receptor KIR2DS1. We find that KIR2DL1-binding RIFINs can also bind to KIR2DS1, resulting in activation of KIR2DS1-expressing NK cells. This study demonstrates for the first time that activating KIRs can recruit natural killer cells to target a pathogen and reveals a potential role for activating immune receptors in control of malaria infection

2025-01-15 | GSE286478 | GEO

E-GEOD-17508

Project description:Identification of human miR-22-responsive transcripts in MCF7 cells

2025-01-24 | E-GEOD-17508 | ExpressionAtlas

E-PROT-34

Project description:Allele-Specific Protein Abundance in Human Brain

2022-01-06 | E-PROT-34 | ExpressionAtlas

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

Project description:Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. Combined with hepatic arterial infusion chemotherapy (HAIC), this study is conducted to assess the efficacy and safety of this regimen in patients with unresectable colorectal cancer liver metastases as the third-line therapy.

| 2733287 | ecrin-mdr-crc

Molecular Docking and Dynamic Study of Ethanol Extract of Citrus sinensis as Keap-1 and NMDA inhibitor in Brain Injury

Project description:<p>Traumatic brain injury is a significant cause of mortality in young adults and disability in all age groups. Secondary injury involving various processes such as oxidative stress, which induced neuronal apoptosis, ensued afterward. This study aimed to analyze the active compounds of Citrus sinensis and predict its antioxidative activity in traumatic brain injury. Liquid Chromatography High-Resolution Mass Spectrometry (LC-HRMS) was used to identify compounds in ethanol extract of Citrus sinensis peel. We analyzed pharmacokinetics, blood-brain barrier (BBB) permeability and toxicity of active compounds in Citrus sinensis peel using SwissADME and OSIRIS. The compounds have good blood-brain barrier permeability conducted for molecular docking study to identify molecular interaction with Keap1 (Kelch-like ECH Associated Protein 1) and NMDA (N-methyl-D-aspartate) proteins using PyRx, PyMol and Discovery Studio software. Results of the LC-HRMS examination obtained 16 active compounds contained in the ethanol extract of the orange peel. Nootkatone, alminoprofen, linoleic acid, chanoclavine, scoparone and tangeretin are predicted to pass the blood-brain barrier. Active compounds of Citrus sinensis strongly bond against Keap1 and NMDA, especially Scoparone and Nootkatone. The strong binding affinity of scoparone-Keap1 was -5.0, more than the control ligand, and nootkatone-NMDA was -7.8, similar to the control ligand. Active compounds of Citrus sinensis peel showed inhibitory potentials, good pharmacokinetics and toxicity profiles against Keap1 and NMDA. These findings suggested that ethanol extract of Citrus sinensis peels has the potential as an oxidative stress inhibitor for brain injury therapy.</p>

2023-01-02 | MTBLS5785 | MetaboLights

E-GEOD-16238

Project description:Genome-wide identification of binding sites of Evi1 in human myeloid cell lines

2025-01-24 | E-GEOD-16238 | ExpressionAtlas

E-GEOD-37603

Project description:Identification of WISP1 as an important survival factor in human mesenchymal stem cells

2025-01-24 | E-GEOD-37603 | ExpressionAtlas

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Project description:Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study.

| 2154098 | ecrin-mdr-crc